Vorasidenib Continuous Therapy Guide: Dosing Strategy and Management for Glioma

　　1.Overview and Treatment Strategy

　　Vorasidenib is an oral targeted therapy for eligible glioma patients.It works by continuously inhibiting mutant IDH1/IDH2 activity to delay disease progression.The standard regimen is once-daily oral dosing,continued until disease progression or unacceptable toxicity—not based on a fixed number of cycles.

　　2.Continuous Treatment and Discontinuation

　　Treatment should not be stopped automatically after a certain number of months if the disease is controlled and the drug is well tolerated.Even if imaging shows temporary stability,patients should not discontinue on their own,as tumor-related molecular activity may persist.Decisions to continue require comprehensive assessment of imaging,disease changes,and tolerability.If treatment is interrupted and needs to be restarted,resumption should not follow the original schedule blindly but be re-evaluated by a physician.

　　3.Toxicity Management and Dose Adjustment

　　Liver function abnormalities are a key concern.The FDA recommends baseline liver tests before starting and close monitoring early in treatment.If transaminase elevations occur,actions may include temporary interruption,dose reduction after recovery,or permanent discontinuation.Other unacceptable toxicities also require prompt adjustment or termination.

　　4.Missed Dose and Vomiting

　　If a dose is missed and remembered within 6 hours,take it as soon as possible.If more than 6 hours have passed,skip the missed dose and take the next dose at the regular time.Do not double the next dose to compensate.No additional dose is needed if vomiting occurs after taking the drug.

　　5.Core Reminders

　　Vorasidenib requires long-term continuous use.Patients should not self-discontinue,change the dose,or alter the schedule due to symptom improvement,short-term stable scans,or mild discomfort.All therapeutic decisions must be guided by a physician.